SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Vitamin D Deficiency

Keck School of Medicine of USC

V. Gevorgyan

COVID-19 & ICU FAQ Answered: When Should We Intubate & How Do We Adj…

Hassan Bencheqroun MD FCCP

EHRA 2024: Ongoing Clinical Investigations with Cardiac Contractilit…

CCM® Therapy

N. Varma

Implementation of Drug Therapies for Heart Failure with Reduced Ejec…

Michigan Medicine

J. Golbus

EHRA 2024: Real-World Experience with Cardiac Contractility Modulati…

CCM® Therapy

J. Kuschyk

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

EHRA 2024: Cardiac Contractility Modulation: Innovative Therapy for …

CCM® Therapy

V. Reddy, N. Varma, K. Kuck, J. Kuschyk, N. Aspromonte

AHA 2024 Insights: MayaRED - Revolutionizing Hospital Discharge Thro…

AHA 2024 Insights

A. Mohammadi

Coronary Microvascular Disease in HFpEF: Pathophysiology, Diagnosis …

MUSC Cardiology

S. Mohammed

CHEST 2021: Patient With Intermediate Risk-PE Should Go for Thrombol…

CHEST 2021 Coverage

B. Dalal

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money

ATS 2023 Insights: To PAP or Not to PAP - Heart Failure and Sleep Di…

Vaishnavi Kundel

V. Kundel

EHRA 2024: Unmet Medical Needs in Heart Failure Management: Can Devi…

CCM® Therapy

N. Aspromonte

COVID-19 and Heart Failure

24th Annual Heart Failure 2020: an Update on Therapy

M. Mehra